Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has secured a multi-million pound contract with a leading multi-billion dollar global ecommerce provider of reagents and tools to the research and clinical community.

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

As part of the agreement, Oxford Genetics will leverage its high throughput automated genomic engineering platform for CRISPR modification of mammalian cell lines.

Ryan Cawood, CEO, Oxford Genetics said: “This contract highlights Oxford Genetics’ commitment to providing the highest quality cell line engineering services to its global customer base and continuing to add value to their operations. We have moved away from manual processing, which is the norm in this market, in favour of automated, scalable platforms.

“This approach means we are well positioned to deliver the large number of custom-engineered cell lines per year that the global market is forecast to need.

“We are excited about this project which will see us significantly expand our product portfolio and continue to deliver innovative products and solutions to the pharmaceutical industry.”

Headquartered in Oxford, UK, Oxford Genetics is a leading synthetic biology company dedicated to developing and delivering technologies and services to its customers that will help to change the gene editing industry. The company’s use of automation allows it to develop new and innovative solutions, the latest of which is its mammalian CRISPR cell line engineering platform.

Read More

Related news

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
Envigo launches PATHWAY to enable FIH clinical trials

Envigo launches PATHWAY to enable FIH clinical trials

11 Mar 2019

PATHWAY manages the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers.

Read more 
Biogen acquisition boosts its ophthalmology pipeline

Biogen acquisition boosts its ophthalmology pipeline

4 Mar 2019

Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.

Read more 
Uniqsis expands LED photoreactor range

Uniqsis expands LED photoreactor range

3 Mar 2019

The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.

Read more 
Crowdfund and discover promising therapeutics via Molecule

Crowdfund and discover promising therapeutics via Molecule

21 Feb 2019

Connecting scientists, patients, and industry to advance drug development in a collaborative open market.

Read more 
Partnership expands to develop a new treatment for pachyonychia congenita

Partnership expands to develop a new treatment for pachyonychia congenita

19 Feb 2019

MedPharm and Palvella Therapeutics hope to develop the first approved treatment for PC in the US and Europe.

Read more 
Chemspace and LabNetwork collaborate to extend access to chemical databases

Chemspace and LabNetwork collaborate to extend access to chemical databases

14 Feb 2019

Collaboration provides drug discovery researchers access to European distribution and local support for library of in-stock and on-demand compounds.

Read more 
SGS to conduct its first malaria human challenge trial in Belgium

SGS to conduct its first malaria human challenge trial in Belgium

13 Feb 2019

The advanced candidate compound undergoing the trial has demonstrated potential to target malaria parasites before they have a chance to establish the symptoms of malaria.

Read more 
New API screening program strengthens Particle Sciences' nanomilling offering

New API screening program strengthens Particle Sciences' nanomilling offering

22 Jan 2019

Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.

Read more 
Preparing samples of cannabis plant for THC/CBD analysis

Preparing samples of cannabis plant for THC/CBD analysis

15 Jan 2019

Porvair Sciences has created a solid, stable and strong microplate that can withstand the applied forces in bead-beaters while maintaining a standard ANSI/SLAS footprint and key dimensions.

Read more